The Content Strategy Gap, Part 1: Why Persona Based Content Strategy Fails Before It Starts

Larry Hines

Part 1 of a three-part series on building a content strategy that actually works in life sciences B2B.

When Good Strategy Goes Nowhere


There's a moment most life sciences marketing leaders recognize, even if they don't talk about it openly. It usually comes about six months after a persona and buyer journey initiative wraps up. Someone pulls up the deliverables (the persona profiles, the journey maps, the messaging framework, etc.) and realizes that none of it is actually driving content decisions. The calendar looks almost identical to what it did before the initiative began. The personas are on a slide deck. The journey map is pinned to a conference room wall. The strategy that generated genuine excitement at kickoff has quietly become shelf ware.


This isn't a failure of the framework. Personas and buyer journey maps are genuinely useful tools when they're built and used correctly. The failure is almost always in execution; and the reasons behind it are more structural than most organizations acknowledge.


The Persona Development Problem

The way most organizations build personas sets them up to fail before the first piece of content is written. Personas are typically developed in a workshop setting, by a marketing team working largely from internal assumptions, and then documented in a format that looks comprehensive but is functionally too vague to drive content decisions. "Senior Lab Manager, 40-55, values efficiency and reliability, influences purchasing decisions" is a demographic description, not a content brief. It tells you who the person is in broad strokes. It tells you almost nothing about what to write for them.


What's missing from most persona development processes is the psychological layer: the specific questions this person is asking at each stage of their evaluation, the objections they raise when they encounter your category, the information gaps that cause them to stall or disengage, and the proof points that actually move them forward. That information doesn't come from internal workshops. It comes from talking to buyers; something most persona development processes treat as optional rather than foundational.


The second problem is isolation. Personas are almost always built by marketing without meaningful input from sales. This is a significant gap, because sales talks to buyers every day. They hear the questions, the objections, the competitive comparisons, and the concerns that never make it into a formal RFP. A persona built without that intelligence is a persona built on assumption,  and each of us marketers understands that assumption-based content often produces content that misses.


The Buyer Journey Map Problem

Buyer journey maps suffer from a related but distinct set of problems. The most common issue is that they reflect how marketing believes buyers behave rather than how buyers actually behave. In life sciences, the buying journey is rarely the clean, linear progression from awareness to consideration to decision that journey maps typically depict. Buyers loop back. They restart evaluations when a stakeholder changes. They spend months in independent research mode before anyone on your team knows they exist. They consult peers and communities that your analytics will never capture.


Most journey maps also stop too early. They document the path to the hand-raise, e.g. the moment a prospect fills out a form or requests a conversation, without adequately accounting for the extended pre-awareness research phase that determines which vendors even make the consideration set. In life sciences, that pre-awareness phase can last months. If your content strategy doesn't serve buyers during that period, you may never get the opportunity to serve them at all.


The third problem is stasis. Journey maps are built, presented, approved, and then rarely updated. The market moves, buyer behavior shifts, new channels emerge — including AI-powered search tools that are fundamentally changing how buyers find and evaluate vendors — and the journey map stays exactly as it was on the day it was completed. A static map driving a dynamic content strategy is a map that becomes less useful with every passing quarter.


Why Life Sciences Amplifies Every One of These Problems

The structural challenges of persona-based content strategy exist in most B2B industries. In life sciences, they're more acute. Sales cycles in biotech, medtech, and lab automation frequently run six to eighteen months. That means the content strategy has to account for sustained, independent buyer research over an extended period , and not just a few touchpoints before a sales conversation. A journey map that doesn't reflect this reality will consistently misallocate content investment toward the wrong stages.


The buying committee in life sciences is also more complex than in most industries. A single capital equipment or software purchase might involve a principal investigator, a lab director, a procurement team, an IT stakeholder, and a C-suite approver, each with different questions, different information sources, and a different definition of a successful outcome. Building one or two personas and calling the buying committee covered is a shortcut that shows up as lost deals.


Technical audiences add another layer. Scientists and researchers expect a level of content depth and specificity that generic persona frameworks don't anticipate. A drug developer isn't moved by vague promises of 'streamlined workflows.' They want to understand how your system integrates with their existing liquid handling platform, what the throughput implications are for their specific assay format, and what the validation requirements look like for a GMP environment. Producing that content requires more than a persona profile. It requires genuine subject matter expertise and a content development process that can support it.


The Organizational Failure Underneath the Tactical Failure

Behind the persona development and journey mapping problems is a more fundamental organizational failure: the absence of the systems and structures needed to make a content strategy function as an ongoing discipline rather than a one-time initiative. The most common symptom is the missing feedback loop. In nearly all of the organizations I've worked for or consulted with, most have no formal mechanism for connecting content performance data back to persona assumptions. If a white paper written for the economic buyer is getting almost no engagement, that's a signal. It's  either an irrelevant topic, the format is wrong, the channel is wrong, or the persona assumption underlying the content is wrong. Without a process for asking and answering that question, the same mistakes get repeated in the next content cycle.


Sales and marketing misalignment compounds this. The content marketing is often disconnected from the questions sales is actually hearing in the field. Sales reps build their own ad hoc materials to fill the gaps (one-pagers, slide decks, even brochures) that are inconsistent, off-brand, off-message, and invisible to the marketing team. The result is two parallel content ecosystems that never inform each other.


Volume pressure is the final organizational trap. When content teams are measured on output, e.g. posts published, assets produced, campaigns launched, the path of least resistance is content that's easy to create, not content that's strategically targeted. Checking the persona box by adding a generic "for lab managers" tag to a piece of content is not the same as creating content that serves a lab manager's specific needs at a specific buying stage. In an environment that rewards volume, the distinction gets lost.


The Sustainability Problem: Why Programs That Launch Well Still Fail

Perhaps the most underappreciated failure mode in persona-based content strategy is this: the program launches successfully, generates real momentum, produces genuine deliverables, and then quietly degrades over the following twelve to eighteen months until it exists in name only.

This pattern is so common in large marketing organizations that it has almost become accepted as inevitable. It isn't inevitable, but understanding why it happens is a prerequisite for preventing it.


Leadership changes are the single most disruptive factor. A new CMO or VP of Marketing arrives with their own strategic priorities, their own preferred frameworks, and their own mandate to put their stamp on the function. The existing persona and content strategy — regardless of its quality — gets questioned, restructured, or quietly set aside in favor of whatever the new leader wants to build. Months or years of accumulated institutional knowledge about buyers, messaging, and content performance can be lost in a single leadership transition.


The discipline required to sustain the program is consistently underestimated at launch. Running a functioning persona-based content strategy requires ongoing editorial governance, regular cross-functional alignment between sales and marketing, and a level of process rigor that competes with every other priority on a busy marketing team's plate. In the first few months, when the initiative is new and energy is high, that rigor is relatively easy to maintain. As the novelty fades and other priorities accumulate, it becomes progressively more difficult to sustain.


Training and retraining is a continuous investment that most organizations treat as a one-time event. As team members turn over, institutional knowledge about the personas, the messaging architecture, and the editorial rationale leaves with them. New team members need to be onboarded into the framework, which takes time and leadership attention that is rarely budgeted for. Without it, new hires default to their own instincts and prior habits, and the framework erodes from within.


Updating the strategy when new learnings emerge requires both a process and a culture that most organizations haven't built. What sales is learning in the field, what content performance data is revealing, what win/loss analysis is surfacing is that all of this should be flowing back into the persona and journey map assumptions on a regular basis. In most organizations I've worked for, it doesn't. The strategy calcifies while the market moves, and the gap between the documented framework and the actual buyer reality widens with every quarter it goes unaddressed.


The compounding effect of these factors is what produces the shelf ware outcome. Each factor is manageable in isolation. When leadership changes coincide with team turnover, competing priorities, and an absent feedback loop, the program doesn't just stagnate, it actively deteriorates, often without anyone explicitly deciding to abandon it.


The Underlying Point

Persona-based content strategy is not a project. It's an operating model. The difference between organizations that make it work and those that produce expensive shelf ware isn't the quality of the initial deliverables, it's whether the organization has built the systems, disciplines, and leadership commitment to sustain the framework over time.


That's a harder problem than building a good persona profile. It's also the problem worth solving because the compounding value of a well-maintained content strategy is one of the most durable competitive advantages available to a life sciences marketing organization. Part 2 of this series will examine a specific and underappreciated symptom of these failures: not all personas are treated equally, and the ones that get the least content attention are often the most influential in closing a deal.


I work with life sciences companies on digital marketing strategy, from SEO/AEO and content to demand generation, positioning and messaging, omnichannel campaigns, product launches, voice of customer, and more. If this resonated, or if you have a different perspective, I'd genuinely like to hear from you.


A digital globe made of floating photo and video thumbnails on a black background.

The Content Strategy Gap, Part 3: What a Sophisticated Persona-Based Content Strategy Actually Looks Like

By Larry Hines • June 2, 2026
Explore a sophisticated persona-based content strategy for life sciences B2B. Improve your approach with buyer intelligence insights.
A globe made of floating digital screens and photos on a black background, with “Part 1 of 3” in the corner.

The Content Strategy Gap, Part 2: Are All Personas Treated Equally?

By Larry Hines • May 18, 2026
Most life sciences content strategies serve the technical evaluator well and leave everyone else behind. Learn why buying committee coverage breaks down and what to do about it.
Scientific rendering of molecular structure.

From Fragmented to Unified: Building an Omnichannel Strategy for Complex B2B Buying Committees

By Larry Hines • April 21, 2026
From Fragmented to Unified: Building an Omnichannel Strategy for Complex B2B Buying Committees There's a conversation that happens in a lot of life sciences marketing teams, usually triggered by a lost deal or a pipeline review that doesn't add up. Someone asks: "How did they find us?" And the answer is almost always more complicated than anyone expected. They read a blog post six months ago. They saw you at a conference. Someone on their team got an email. Their scientist looked you up after a webinar. Their procurement lead ran a Google search. Nobody talked to sales until month four. This is the reality of modern B2B buying in life sciences — and it's the reason omnichannel strategy matters as much as it does. The challenge in 2026 isn't deciding where to show up. It's making every touchpoint feel like part of the same coherent conversation, whether a buyer encountered you on LinkedIn last Tuesday or at a tradeshow six months ago. The Buying Committee Problem Before getting into tactics, it helps to name the specific challenge that makes omnichannel strategy genuinely hard in life sciences. You're rarely selling to one person. Capital equipment purchases might involve a principal investigator or lab director who evaluates technical and clinical fit, a procurement team focused on price and vendor compliance, an IT or informatics stakeholder who cares about integration and data security, and a C-suite or finance lead who signs off on budget. Each of these people has different questions, different information sources, and different definitions of a good vendor. Generally, they don't coordinate their research with each other. They're consuming content independently, at different points in the buying cycle, through different channels. And they're forming opinions about your company long before anyone on your team knows they exist. An omnichannel strategy for this environment isn't about broadcasting the same message everywhere. It's about understanding who is likely to show up on which channel, what they need to see when they get there, and how to make those separate encounters feel like a continuous, coherent brand experience. What "Omnichannel" Actually Means (And What It Doesn't) The word gets misused enough that it's worth being direct about the distinction. Multichannel marketing means being present on multiple channels. You have a website, a LinkedIn page, an email program, and you exhibit at conferences. Each channel operates independently. The email team (I’m using “team” loosely; often this is one person) doesn't know what happened at the tradeshow. The website doesn't reflect what sales is saying in conversations. The LinkedIn content has nothing to do with the nurture sequence someone is getting in their inbox. Omnichannel marketing means those channels are coordinated. The story a buyer hears on LinkedIn connects to the content they find on your website, which connects to the follow-up they receive after downloading a white paper, which connects to the conversation a sales rep has with them three months later. Every touchpoint knows, in some sense, what the others have been saying. The gap between these two states is where most life sciences companies currently live. They're multichannel by presence and siloed by execution. Fixing that gap is the actual work of your omnichannel strategy. The Channels That Matter Most in Life Sciences B2B Not every channel deserves equal investment, and life sciences buying behavior is specific enough to make some clear prioritization possible. LinkedIn is the primary digital channel for professional discovery and brand building in this space. Decision-makers, scientists, and procurement leads all have a LinkedIn presence, and it's where thought leadership content gets the most traction. For companies targeting a defined set of accounts, LinkedIn's targeting capabilities — by job title, company, industry, seniority — are genuinely valuable, and they're not dependent on third-party cookies. Organic content from company leadership builds familiarity over time; paid campaigns can accelerate awareness with specific personas at specific accounts. Side note: LinkedIn is primarily a brand-building channel in this context, not a lead generation engine — the platform's value lies in creating familiarity and credibility with the right audiences over time, not in driving direct conversions from a single post or campaign. Email remains one of the highest-ROI channels in B2B when it's done well. This means segmented, relevant, and paced for a long buying cycle. A scientist interested in mass spectrometry, and a procurement lead evaluating vendor compliance should not be receiving the same email sequence nor messaging. The ability to tailor content to the role and buying stage is what separates email programs that generate pipeline from email programs that generate unsubscribes. Content, SEO, and AEO function as the always-on layer of your omnichannel strategy. When a buyer is in independent research mode (which, in life sciences, is most of the time), they're searching for answers through both traditional search engines and increasingly through AI-powered answer engines like ChatGPT, Perplexity, and Claude. Being present at those moments — whether as a ranked result in Google or as a cited source in an AI-generated answer — requires genuinely useful, technically credible content that is structured for both human readers and AI retrieval. Blog posts, white papers, application notes, and FAQs all serve this function, and when built with both SEO and AEO in mind, they extend your brand's reach across every channel where independent buyer research is happening. Tradeshows and events remain disproportionately important in life sciences relative to other industries. The concentration of relevant buyers at events like the American Academy of Clinical Research (AACR), Society of Toxicology (SoT), or the Radiological Society of North America (RSNA) creates relationship-building opportunities that digital channels can't fully replicate. But events work best as part of an omnichannel sequence, not as standalone tactics. More on this in a future post specifically on tradeshow strategy. Direct outreach and sales engagement is the channel where the buying committee question becomes most acute. Sales reps need to know what each contact has engaged with, what channel they came from, and where they are in their evaluation. Without that context, outreach feels generic and the relationship starts from zero even when the prospect has already consumed significant content. Building Coordination Across Channels The tactical question is how to actually connect these channels so they function as a system rather than a collection of independent programs. Start with your CRM and marketing automation platform as the connective tissue. Every meaningful digital interaction — content downloads, email opens and clicks, webinar registrations, website page visits, form fills — should be captured in a system that gives both marketing and sales visibility into what a contact or account has engaged with. HubSpot, Marketo, and Salesforce Marketing Cloud are the most common platforms in this space. If your CRM and marketing automation aren't talking to each other, channel coordination is almost impossible to achieve. Build content for the full buying committee, not just one persona. Map your content assets to the specific questions each stakeholder is asking at each stage of the buying process. Technical application notes and scientific webinars for the research and evaluation stakeholders. ROI frameworks, vendor evaluation guides, and compliance documentation for procurement and finance. Executive-level thought leadership for C-suite contacts. When a buying committee member arrives at your website or LinkedIn page, they should quickly find content that speaks to their specific context. Use account-level engagement as your coordination signal. In a buying committee sale, individual lead scores can be misleading. What matters is whether the account as a whole is showing increased engagement across multiple contacts and channels. This is the logic behind account-based marketing: rather than tracking individual leads in isolation, you track account-level activity and use that signal to coordinate timing and messaging across channels. When multiple stakeholders at the same account are engaging simultaneously, that's a signal worth acting on. Make your brand voice consistent across every channel. This sounds obvious and is surprisingly hard to execute. The tone and perspective in your LinkedIn posts should match the voice in your email nurture sequences, which should match what a sales rep says in an introductory call. When these feel misaligned, buyers notice, and it creates a subtle but real trust erosion. Messaging architecture (which we'll cover in a dedicated post on positioning) provides the foundation for this consistency. The Measurement Challenge Omnichannel strategy introduces a measurement complexity that simpler, single-channel programs don't face: when a deal closes after a buyer has touched six different channels over eight months, which channel gets credit? The honest answer is that no attribution model handles this perfectly. Last-click attribution, which is still the default in many organizations, dramatically overstates the role of the final touchpoint and undercounts everything that built awareness and consideration earlier in the cycle. Realistically, there’s no one marketing tactic or channel that is going to convert a complex life science sale on its own. It’s always the sales representative and science/technical support that are 100% responsible for making these complex sales. Marketing is a critical lever to build brand awareness and equity; soften the market so it’s prepared to hear how the product or service will solve their problems; and deliver market and customer insights that fuel the next innovation. At the same time, we must be able to evaluate our multi-channel campaigns and understand whether we are reaching the appropriate target audience with the correct messaging and influencing the final decision. Multi-touch attribution is better in theory but requires clean data across all channels and a level of technical integration that some marketing teams haven't achieved. The practical approach is to use attribution models directionally rather than definitively, supplement them with direct conversation (asking buyers in sales calls and onboarding surveys how they found you and what influenced their decision), and focus reporting on pipeline contribution and revenue influence rather than trying to achieve perfect attribution precision. What you're ultimately trying to measure is whether the coordinated system is working: are target accounts progressing through the buying cycle? Are multiple stakeholders within key accounts engaging? Is the handoff from marketing to sales happening with enough context to make sales conversations more productive? The Real Goal Omnichannel strategy is sometimes presented as a technology problem, a question of which platforms to integrate and which tools to deploy. Technology enables it, but the underlying goal is simpler and more human than any platform. The goal is to make every buyer feel like your company already understands them when they finally raise their hand. That the sales rep who calls knows what they've read. That the proposal reflects the specific concerns they've expressed. That the brand they've been encountering across channels for the past several months feels like a coherent, credible, trustworthy partner for a high-stakes decision. In life sciences, where the buying cycle is long, the buying committee is complex, and trust is the deciding factor in most competitive situations, that feeling of coherence is worth more than any individual channel can deliver on its own. That's what an omnichannel strategy actually build s. I work with life sciences companies on digital marketing strategy, from SEO and content to demand generation, positioning and messaging, omnichannel campaigns, product launches, voice of customer, and more. If this resonated, or if you have a different perspective, I'd genuinely like to hear from you.